Related Experiment Video
Updated: Jun 25, 2026
09:38
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Chronic inflammatory demyelinating polyneuropathy after treatment with interferon-alpha.
Makoto Hirotani1, Hitoshi Nakano, Shigehisa Ura
1Department of Neurology, Hokkaido University Graduate School of Medicine, Sapporo. hirotani@med.hokudai.ac.jp
Internal Medicine (Tokyo, Japan)
|March 3, 2009
Summary
Interferon-alpha (IFN-alpha) therapy for hepatitis C may trigger autoimmune disorders like chronic inflammatory demyelinating polyneuropathy (CIDP). Intravenous immunoglobulin effectively treated the patient
Area of Science:
- Immunology
- Neurology
- Hepatology
Background:
- Interferon-alpha (IFN-alpha) is a common treatment for chronic viral hepatitis.
- IFN-alpha therapy has been linked to the development of autoimmune disorders.
Observation:
- A patient with chronic hepatitis C virus infection developed chronic inflammatory demyelinating polyneuropathy (CIDP) after starting IFN-alpha treatment.
- Neurological symptoms persisted despite IFN-alpha discontinuation.
Findings:
- The patient's CIDP symptoms significantly improved with intravenous immunoglobulin (IVIG) treatment.
- This suggests a potential immune-mediated mechanism linking IFN-alpha and CIDP.
Implications:
- This case highlights a potential adverse effect of IFN-alpha therapy.
- Understanding this immune mechanism could inform future treatment strategies for CIDP.
- Further research is warranted to explore the relationship between IFN-alpha and autoimmune neuropathies.
Related Concept Videos
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:28Diphtheria
Diphtheria is an acute, toxin-mediated infectious disease that primarily affects the upper respiratory tract. It is caused by Corynebacterium diphtheriae, a Gram-positive, pleomorphic rod that lacks spore-forming capability and exhibits a characteristic club-shaped morphology under microscopic examination. While C. diphtheriae can asymptomatically colonize mucosal surfaces, clinical disease manifests only when the bacterial strain is lysogenized by a specific β-corynephage. This phage...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...